FOLD
vs
E
EPE
FOLD
Over the past 12 months, FOLD has significantly outperformed EPE, delivering a return of +47% compared to the EPE's 0% growth.
Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
Smart Verdict
AI-Powered
Let AI Decide.
FOLD
Valuation Comparison
| Company | Last Price | Intrinsic Value | DCF Value | Relative Value | Wall St Target | ||
|---|---|---|---|---|---|---|---|
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
14.27
USD
|
|||||
|
E
|
Epizyme Inc
F:EPE
|
559
EUR
|
|||||
Compare the stock's valuation with its competitors.
Growth Comparison
Growth Over Time
FOLD, EPE
Compare company's financials with its competitors.
| Company | LTM | Historical Growth | Growth Streak | % Positive Years | Max Drawdown | Volatility | Forecasted Growth | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 10 Years | 1 Year | 3 Years | ||||||||
|
|
Amicus Therapeutics Inc
Revenue
|
|||||||||||
|
E
|
Epizyme Inc
Revenue
|
|||||||||||
All metrics are calculated based on data from the last 10 years.
Compare company's financials with its competitors.
Profitability Comparison
Free Cash Flow
FOLD, EPE
Compare company's free cash flow with its competitors.
| Company | LTM | Average | Historical Growth | FCF Margin | Conversion | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Years | 5 Years | 3 Years | 5 Years | 10 Years | ||||||
|
|
Amicus Therapeutics Inc
NASDAQ:FOLD
|
|||||||||
|
E
|
Epizyme Inc
F:EPE
|
|||||||||
Compare company's free cash flow with its competitors.
Operating Margin
| LTM | 3Y Avg | 5Y Avg | 10Y Avg | ||
|---|---|---|---|---|---|
|
|
Amicus Therapeutics Inc | ||||
|
E
|
Epizyme Inc | ||||
Solvency Comparison
Compare company's equity waterfall with its competitors.
Stocks Performance
Stocks Performance
FOLD, EPE
Performance Gap
FOLD, EPE
Performance By Year
FOLD, EPE
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
